Speciality: Cardiology
Description:
.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM.
Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.
Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
2.
Clinical trial is testing whether heavy lifting could combat cancer side effects
3.
NIH research cuts leave cancer patient facing hard choice
4.
Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.
5.
A video animation guide to assist young people who are fatigued from cancer.
1.
Hematology Drug Preparation Safety: Ensuring Efficacy and Reducing Risks in Clinical Practice
2.
The Latest Advances in Glioblastoma Treatment and Prevention
3.
AI-Assisted Real-Time Tumor Mapping During Surgery: Transforming Intraoperative Oncology
4.
Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology
5.
Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation